JP2020510016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510016A5 JP2020510016A5 JP2019548450A JP2019548450A JP2020510016A5 JP 2020510016 A5 JP2020510016 A5 JP 2020510016A5 JP 2019548450 A JP2019548450 A JP 2019548450A JP 2019548450 A JP2019548450 A JP 2019548450A JP 2020510016 A5 JP2020510016 A5 JP 2020510016A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- upadacitinib
- patient
- baseline
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 75
- WYQFJHHDOKWSHR-MNOVXSKESA-N (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide Chemical compound CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1C1=CN=C2N1C(C=CN1)=C1N=C2 WYQFJHHDOKWSHR-MNOVXSKESA-N 0.000 claims 70
- 229950000088 upadacitinib Drugs 0.000 claims 70
- 239000012458 free base Substances 0.000 claims 35
- 239000007787 solid Substances 0.000 claims 35
- 208000011231 Crohn disease Diseases 0.000 claims 34
- 239000003246 corticosteroid Substances 0.000 claims 15
- 239000002955 immunomodulating agent Substances 0.000 claims 15
- 229940121354 immunomodulator Drugs 0.000 claims 15
- 238000011282 treatment Methods 0.000 claims 15
- 206010012735 Diarrhoea Diseases 0.000 claims 14
- 239000007788 liquid Substances 0.000 claims 14
- 208000004998 Abdominal Pain Diseases 0.000 claims 12
- 229960001334 corticosteroids Drugs 0.000 claims 10
- 230000013872 defecation Effects 0.000 claims 10
- 230000003442 weekly effect Effects 0.000 claims 9
- 230000002584 immunomodulator Effects 0.000 claims 5
- 208000031481 Pathologic Constriction Diseases 0.000 claims 3
- 208000025865 Ulcer Diseases 0.000 claims 3
- 208000037804 stenosis Diseases 0.000 claims 3
- 230000036262 stenosis Effects 0.000 claims 3
- 231100000397 ulcer Toxicity 0.000 claims 3
- 238000001839 endoscopy Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023177288A JP2024009963A (ja) | 2017-03-09 | 2023-10-13 | クローン病及び潰瘍性大腸炎を処置する方法 |
| JP2025207808A JP2026041823A (ja) | 2017-03-09 | 2025-11-28 | クローン病及び潰瘍性大腸炎を処置する方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469337P | 2017-03-09 | 2017-03-09 | |
| US62/469,337 | 2017-03-09 | ||
| US201762470565P | 2017-03-13 | 2017-03-13 | |
| US62/470,565 | 2017-03-13 | ||
| US201762483289P | 2017-04-07 | 2017-04-07 | |
| US62/483,289 | 2017-04-07 | ||
| US201762593629P | 2017-12-01 | 2017-12-01 | |
| US62/593,629 | 2017-12-01 | ||
| PCT/US2018/021800 WO2018165581A1 (en) | 2017-03-09 | 2018-03-09 | Methods of treating crohn's disease and ulcerative colitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177288A Division JP2024009963A (ja) | 2017-03-09 | 2023-10-13 | クローン病及び潰瘍性大腸炎を処置する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510016A JP2020510016A (ja) | 2020-04-02 |
| JP2020510016A5 true JP2020510016A5 (OSRAM) | 2021-04-22 |
Family
ID=61750557
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019548450A Pending JP2020510016A (ja) | 2017-03-09 | 2018-03-09 | クローン病及び潰瘍性大腸炎を処置する方法 |
| JP2023177288A Pending JP2024009963A (ja) | 2017-03-09 | 2023-10-13 | クローン病及び潰瘍性大腸炎を処置する方法 |
| JP2025207808A Pending JP2026041823A (ja) | 2017-03-09 | 2025-11-28 | クローン病及び潰瘍性大腸炎を処置する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023177288A Pending JP2024009963A (ja) | 2017-03-09 | 2023-10-13 | クローン病及び潰瘍性大腸炎を処置する方法 |
| JP2025207808A Pending JP2026041823A (ja) | 2017-03-09 | 2025-11-28 | クローン病及び潰瘍性大腸炎を処置する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190046527A1 (OSRAM) |
| EP (2) | EP3592353A1 (OSRAM) |
| JP (3) | JP2020510016A (OSRAM) |
| CN (2) | CN110392572A (OSRAM) |
| AU (2) | AU2018230500B2 (OSRAM) |
| BR (1) | BR112019018576A2 (OSRAM) |
| MX (2) | MX2019010733A (OSRAM) |
| TW (2) | TWI851536B (OSRAM) |
| WO (2) | WO2018165581A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) * | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913999PA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| TWI851536B (zh) | 2017-03-09 | 2024-08-11 | 美商艾伯維有限公司 | 治療克羅恩氏病和潰瘍性結腸炎之方法 |
| US11564922B2 (en) | 2017-03-09 | 2023-01-31 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
| CN112770756A (zh) * | 2018-09-29 | 2021-05-07 | 苏州科睿思制药有限公司 | 一种Upadacitinib的晶型及其制备方法和用途 |
| WO2020115212A1 (en) * | 2018-12-05 | 2020-06-11 | Lek Pharmaceuticals D.D. | Crystalline phosphate salt of selective jak1 inhibitor upadacitinib |
| CN111909160B (zh) * | 2019-05-09 | 2024-05-28 | 苏州鹏旭医药科技有限公司 | 一种乌帕替尼盐类化合物及其制备方法 |
| CN110101669A (zh) * | 2019-06-11 | 2019-08-09 | 南京新酶合医药科技有限公司 | 一种乌帕替尼颗粒的生产工艺 |
| EP4356963A3 (en) | 2019-09-30 | 2024-07-17 | AbbVie Inc. | Treating spondyloarthritic and psoriatic conditions with upadacitinib |
| KR20230038229A (ko) | 2020-07-08 | 2023-03-17 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도 |
| US20240316040A1 (en) * | 2020-12-29 | 2024-09-26 | Abbvie Inc. | Extended release upadacitinib formulations |
| CN114380837B (zh) * | 2021-12-27 | 2023-06-30 | 上海邈金医药科技有限公司 | 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用 |
| MX2024008557A (es) * | 2022-01-13 | 2024-09-11 | Abbvie Inc | Método de administración de upadacitinib para evitar interacciones farmacologicas y efectos adversos. |
| US20250099463A1 (en) * | 2022-01-20 | 2025-03-27 | Renata Pharmaceuticals (Ireland) Limited | Sustained Release Pharmaceutical Composition of Upadacitinib |
| AU2023337007A1 (en) * | 2022-09-09 | 2025-03-13 | Intas Pharmaceuticals Ltd. | Upadacitinib formulation |
| US12531141B2 (en) * | 2023-01-17 | 2026-01-20 | Children's Hospital Medical Center | Model-informed precision dosing systems for treatment of inflammatory bowel disease |
| WO2025149974A1 (en) * | 2024-01-11 | 2025-07-17 | Takeda Pharmaceutical Company Limited | Combination therapy with an anti-alpha4beta7 antibody |
| CN120699157B (zh) * | 2025-07-16 | 2025-12-16 | 安康市中心医院 | 一种治疗溃疡性结肠炎的恢复肠屏障功能抗体及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| JP2007537296A (ja) | 2004-05-14 | 2007-12-20 | アボット・ラボラトリーズ | 治療薬としてのキナーゼ阻害薬 |
| CN100381175C (zh) | 2004-10-09 | 2008-04-16 | 山西中医学院 | 一种微乳制剂及其制备方法 |
| TW200801008A (en) | 2005-12-29 | 2008-01-01 | Abbott Lab | Protein kinase inhibitors |
| MX2009003650A (es) | 2006-10-06 | 2009-04-22 | Abbott Lab | Nuevos imidazotiazoles e imidazoxazoles. |
| MX2009012030A (es) | 2007-05-07 | 2010-01-25 | Evonik Roehm Gmbh | Formas farmacéuticas sólidas compuestas de un recubrimiento enterico con liberación acelerada del medicamento. |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| JP2011515438A (ja) | 2008-03-28 | 2011-05-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸ペレットの製造方法 |
| RU2015105591A (ru) | 2008-06-10 | 2015-08-10 | Эббви Инк. | Новые трициклические соединения |
| CN101904814A (zh) | 2009-06-04 | 2010-12-08 | 上海恒瑞医药有限公司 | 制备载药乳剂的方法 |
| EP2459180A1 (en) | 2009-07-31 | 2012-06-06 | Ranbaxy Laboratories Limited | Multi-layered, multiple unit pharmaceutical compositions |
| JP5607174B2 (ja) | 2009-12-01 | 2014-10-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| FR2991171B1 (fr) | 2012-06-01 | 2014-05-23 | Galderma Res & Dev | Procede de preparation d'une composition dermatologique comprenant des oleosomes |
| JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
| WO2015061665A1 (en) * | 2013-10-24 | 2015-04-30 | Abbvie Inc. | Jak1 selective inhibitor and uses thereof |
| SG11201701292XA (en) | 2014-08-27 | 2017-03-30 | Abbvie Inc | Topical formulation |
| US12133911B2 (en) | 2015-06-09 | 2024-11-05 | Capsugel Belgium Nv | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913999PA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN110072519A (zh) * | 2016-12-14 | 2019-07-30 | 普罗根尼蒂公司 | 使用jak抑制剂治疗胃肠道疾病及装置 |
| TWI851536B (zh) * | 2017-03-09 | 2024-08-11 | 美商艾伯維有限公司 | 治療克羅恩氏病和潰瘍性結腸炎之方法 |
-
2018
- 2018-03-09 TW TW107108166A patent/TWI851536B/zh active
- 2018-03-09 EP EP18712786.5A patent/EP3592353A1/en not_active Withdrawn
- 2018-03-09 CN CN201880016862.XA patent/CN110392572A/zh active Pending
- 2018-03-09 MX MX2019010733A patent/MX2019010733A/es unknown
- 2018-03-09 EP EP24199939.0A patent/EP4487908A3/en active Pending
- 2018-03-09 BR BR112019018576-3A patent/BR112019018576A2/pt not_active Application Discontinuation
- 2018-03-09 US US15/917,013 patent/US20190046527A1/en not_active Abandoned
- 2018-03-09 AU AU2018230500A patent/AU2018230500B2/en active Active
- 2018-03-09 WO PCT/US2018/021800 patent/WO2018165581A1/en not_active Ceased
- 2018-03-09 JP JP2019548450A patent/JP2020510016A/ja active Pending
- 2018-03-09 CN CN202510812764.9A patent/CN120661512A/zh active Pending
- 2018-03-09 TW TW113126496A patent/TW202517269A/zh unknown
-
2019
- 2019-09-09 MX MX2022015499A patent/MX2022015499A/es unknown
-
2020
- 2020-12-09 US US17/115,833 patent/US20210361647A1/en not_active Abandoned
-
2022
- 2022-02-09 WO PCT/US2022/070594 patent/WO2022178492A1/en not_active Ceased
- 2022-04-01 US US17/712,008 patent/US11607411B2/en active Active
-
2023
- 2023-10-13 JP JP2023177288A patent/JP2024009963A/ja active Pending
-
2024
- 2024-05-30 AU AU2024203642A patent/AU2024203642B2/en active Active
-
2025
- 2025-11-28 JP JP2025207808A patent/JP2026041823A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2454996C2 (ru) | Применение ксантогумола и изоксантогумола в качестве активного вещества для профилактики и/или борьбы с заболеваниями печени | |
| JP6588160B2 (ja) | 物質ｐを含む傷治癒用薬学組成物 | |
| JP2016196419A (ja) | 皮膚外用製剤 | |
| Berry et al. | Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis. | |
| JP2016505050A5 (OSRAM) | ||
| JP7224687B2 (ja) | 局所注射用組成物 | |
| JPS5965013A (ja) | 上部尿路平滑筋拡張剤 | |
| Zeng et al. | LB0001 head-to-head comparison of TLL-018 and tofacitinib in patients with active rheumatoid arthritis: interim results from a phase IIa study | |
| JP2021066751A (ja) | 経口用医薬組成物 | |
| CN107281242A (zh) | 八宝丹及其制剂在制备抑制炎症组织增生药物中的应用 | |
| EP0680756A1 (en) | Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis | |
| EP3283066B1 (en) | 4-phenylbutyric acid derivatives | |
| Syngle | Arthritis and its treatment | |
| CN102512650A (zh) | 一种治疗面神经麻痹的外用药物 | |
| RU2000129499A (ru) | Лечение депрессии и фармацевтические препараты для этой цели | |
| EP0402208A1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
| JPH10175860A5 (OSRAM) | ||
| KR102838311B1 (ko) | Rls 치료를 위한 님 | |
| CN108404094A (zh) | 一种疏络止痛消炎蜂毒应用调理膏 | |
| KR20170140791A (ko) | 부종의 치료, 예방 또는 개선용 조성물 | |
| JP6857619B2 (ja) | Ｎ−［７−［（メチルスルホニル）アミノ］−４−オキソ−６−フェノキシ−４ｈ−１−ベンゾピラン−３−イル］ホルムアミドまたはその塩を含有する医薬組成物 | |
| Bari et al. | Topical Diltiazem Versus Topical Glyceryl Trinitrate In The Management Of Chronic Anal Fissure | |
| SU1382478A1 (ru) | Способ лечени экстрапирамидных заболеваний | |
| JP2016518440A5 (OSRAM) | ||
| CN105616430A (zh) | 一种含有氨基葡萄糖的治疗脂肪肝的药物组合物 |